Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25376887 | 0.94 | PDE2A (0.49) | PDE2APOLBKMT2AGAAHPGD | |
| SCHEMBL25376881 | 0.91 | PDE2A (0.47) | PDE2APOLBKMT2AGAAHPGD | |
| SCHEMBL469235 | 0.82 | POLB (0.43) | PDE2APOLBKMT2AGAAHPGD | |
| SCHEMBL13104238 | 0.82 | POLB (0.43) | PDE2APOLBKMT2AGAAHPGD | |
| SCHEMBL13677362 | 0.82 | POLB (0.43) | PDE2APOLBKMT2AGAAHPGD | |
| SCHEMBL14653779 | 0.81 | KMT2A (0.44) | PDE2APOLBKMT2AGAASCN9A | |
| SCHEMBL22481154 | 0.81 | ADRB2 (0.64) | PDE2AKMT2AADRB2 | |
| SCHEMBL22480813 | 0.81 | ADRB2 (0.64) | PDE2AKMT2AADRB2 | |
| SCHEMBL26925870 | 0.81 | KMT2A (0.47) | PDE2APOLBKMT2AGAASCN9A | |
| SCHEMBL9987907 | 0.81 | KMT2A (0.41) | PDE2APOLBKMT2AGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562828-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250136604-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-11999738-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3562828-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Dart NeuroScience LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018125810-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | PDE2A 333/4885POLB 2100/4885KMT2A 2276/4885 |
| US-11999738-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3B | PDE2A 2/4885POLB 716/4885KMT2A 1601/4885 |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3B | PDE2A 2/4885POLB 716/4885KMT2A 1601/4885 |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, TDP2 | PDE2A 2/4885POLB 658/4885KMT2A 1507/4885 |
| US-20250136604-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3B | PDE2A 2/4885POLB 716/4885KMT2A 1601/4885 |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | PDE2A 2/4885POLB 658/4885KMT2A 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.